🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 16 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/06/2023 19,97 20,83 19,84 20,31 +3,04% 4,98% 949.600
29/06/2023 20,30 20,30 19,54 19,71 -1,94% 3,74% 615.800
28/06/2023 19,35 20,22 18,81 20,10 +4,36% 7,29% 718.300
27/06/2023 18,80 19,36 18,13 19,26 +2,83% 6,54% 682.000
26/06/2023 19,30 19,37 18,59 18,73 -2,65% 4,04% 670.200
23/06/2023 19,18 19,46 18,85 19,24 -0,16% 3,22% 1.478.500
22/06/2023 19,01 19,48 18,82 19,27 +1,90% 3,47% 771.700
21/06/2023 18,77 19,02 17,89 18,91 -0,21% 6,02% 1.222.100
20/06/2023 19,46 19,46 18,67 18,95 -3,02% 4,06% 1.911.400
16/06/2023 19,77 19,77 18,87 19,54 -0,31% 4,58% 4.395.000
15/06/2023 19,36 19,87 18,82 19,60 +0,00% 5,42% 1.510.800
14/06/2023 20,47 20,87 19,55 19,60 -3,83% 6,42% 1.472.900
13/06/2023 20,34 21,15 19,93 20,38 +1,34% 6,00% 1.143.200
12/06/2023 21,07 21,07 19,32 20,11 -4,69% 8,31% 1.729.800
09/06/2023 21,80 21,98 20,88 21,10 -2,50% 5,05% 1.334.800
08/06/2023 20,58 21,74 19,74 21,64 +5,15% 9,72% 1.004.700
07/06/2023 20,00 20,79 19,80 20,58 +2,03% 4,95% 996.300
06/06/2023 20,70 20,70 19,65 20,17 -1,80% 5,07% 1.295.500
05/06/2023 19,93 20,73 18,72 20,54 -2,24% 10,09% 2.057.200
02/06/2023 20,63 21,07 20,16 21,01 +3,50% 4,41% 801.200
01/06/2023 20,19 20,67 19,75 20,30 -1,17% 4,56% 954.200
31/05/2023 20,17 20,91 19,61 20,54 +1,38% 6,45% 1.388.800
30/05/2023 22,13 22,34 20,24 20,26 -8,03% 9,49% 1.658.600
26/05/2023 20,75 22,51 20,75 22,03 +25,89% 8,48% 4.555.900
25/05/2023 18,00 18,00 16,91 17,50 -3,05% 6,06% 1.013.900
24/05/2023 17,99 18,34 17,72 18,05 +0,00% 3,45% 685.500
23/05/2023 18,00 18,69 17,83 18,05 -0,50% 4,78% 770.100
22/05/2023 18,48 18,95 18,01 18,14 -0,71% 5,08% 738.900
19/05/2023 17,70 18,27 17,58 18,27 +3,75% 3,93% 846.000
18/05/2023 17,99 18,38 17,38 17,61 -3,19% 5,53% 916.600